Cialis
Product Images NDC 16590-905

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Cialis (NDC 16590-905). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cialis 10 mg Label Image (Cialis 10 mg Label 905)

Cialis 10 mg tablet packaging label from STAT RX USA LLC, displaying a 10-count package. It states the product is generic for tadalafil 10 mg, with manufacturing by Eli Lilly & Co. Dosage and storage instructions are partially visible, along with warnings about potential side effects such as headaches and flushing. The label includes the NDC number 16590-905-10 and a note that the product is Rx only.*

FDA Label Image

Chemical Structure (Cialis Uspi F001 Structure V1)

Chemical structure diagram of the active ingredient in CIALIS by STAT RX USA LLC, showing molecular bonds and arrangement of atoms in the compound.*

FDA Label Image

Figure (Cialis Uspi F001 V2)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 days of administration. The graph includes error bars indicating variability at each time point.*

FDA Label Image

Figure (Cialis Uspi F002 V1)

Four line graphs illustrating the difference in blood pressure (BP) values between Tadalafil and placebo over 96 hours. The graphs display standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with time in hours on the x-axis and difference in mmHg on the y-axis. Error bars indicate variability at each time point.*

FDA Label Image

Figure (Cialis Uspi F003 V1)

A dual line graph depicting standing and supine systolic blood pressure (mmHg) over time (hours) post-dose. The top graph shows standing systolic BP changes for tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg. The bottom graph shows supine systolic BP changes for the same treatments over 24 hours.*

FDA Label Image

Figure (Cialis Uspi F004 V1)

A line graph depicting systolic blood pressure changes over 12 hours after administration of tadalafil or placebo. The graph includes four plotted lines representing 20 mg tadalafil with 8 mg doxazosin at 08:00 and 20:00, and placebo with 8 mg doxazosin at 08:00, showing their effects on systolic BP (mmHg) over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.